Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.
Seattle, WA, 98102